Lung Cancer

Cancer Challenges

  • Tumor-Only Assessment – Lung cancer trials commonly utilize basic imaging measures like RECIST 1.1 but fail to evaluate more advanced tumor metrics and other aspects of lung health (airways, tissue, cardiac/vascular, function) which may play a role in treatment response, disease progression, and patient selection.
  • Reproducibility – Consistent measures are critical in cancer trials. Is your trial utilizing appropriate levels of AI to aid quality and consistency?
  • Challenging Imaging Operations – Quantitative imaging provides exceptional value in emphysema trials; however, precision imaging can be especially challenging for trial sites. Strict adherence to CT protocols, staff training, scanner calibration, data management and other complexities can result in unsuccessful sites or poor/inconsistent data quality. Long onboarding times or dropout sites can add significant cost to emphysema trials.

“We have a great collaboration. I thoroughly enjoy working with VIDA. It is more like a natural extension of our team and that is the way it should be while working with a partner.”

Chief Scientist

Top 5 Global Pharma Company

VIDA Lung Intelligence for Lung Cancer Clinical Trials

VIDA provides up to 15,000 lung metrics per study, across more than 50 biomarkers. These measures provide trial sponsors with a comprehensive assessment of lung anatomy and function for lung cancer subjects. VIDA’s measures span airways, tissue, vasculature/cardiac, and function, in addition to a full range of nodule characteristics like RECIST, volume, density, shape, and more.

VIDA Intelligence Portal is a respiratory trial imaging orchestration platform designed to ease the imaging operations of a lung trial. Portal applies AI-powered intelligence to automate tasks that are mundane and/or prone to human error. The portal also provides eLearning, quality control, data security, drag and drop data exchange, team communications and much more. The result is clinical trial sites capable of acquiring high quality clinical trial imaging data with ease.

Intelligence services leverage imaging and operational data gold mines to maximize their value for trial sponsors. For example, retrospective data analysis services examine existing datasets to surface valuable new insights. Site performance monitoring gives sponsors dynamic operational dashboards to proactively view the health of trial sites, the data they are submitting, and more. Subject screening services assist sponsors in filtering out candidates who meet exclusion criteria.

Lung Cancer Biomarkers

Please complete the form below for more information on quantitative imaging biomarkers for lung cancer clinical trials.

Lung Cancer Studies Utilizing VIDA’s Precision Imaging

1.
Herth, F. J. F. et al. The Modern Art of Reading Computed Tomography Images of the Lungs: Quantitative CT. Respiration 95, 8–17 (2018).
1.
Choi. The Accuracy of Quantitative CT Scan Based Prediction of Post-Lung Resection FEV1 and DLCO. American Thoracic Society International Conference Meetings Abstracts American Thoracic Society International Conference Meetings Abstracts.